(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 14 March 2002 (14.03.2002)

(10) International Publication Number WO 02/19945 A2

(51) International Patent Classification7:

(21) International Application Number: PCT/US01/27306

(US). WESTRUM, John, W., Jr. [US/US]; 8690 Oak Hill Circle, Prior Lake, MN 55372 (US). CABAK, James, E. [US/US]; 3725 Ximines Lane North, Plymouth, MN 55441 (US).

(22) International Filing Date:

4 September 2001 (04.09.2001)

(74) Agents: INSKEEP, James, W. et al.; Oppenheimer Wolff & Donnelly LLP, Suite 700, 840 Newport Center Drive, Newport Beach, CA 92660-7007 (US).

(25) Filing Language:

English

A61F 2/00

(26) Publication Language:

English

(30) Priority Data:

60/230,647

7 September 2000 (07.09.2000)

(81) Designated States (national): AU, CA, JP, US.

US

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(71) Applicant (for all designated States except US): AMERI-CAN MEDICAL SYSTEMS, INC. [US/US]; 10700 Bren Road West, Minnetonka, MN 55343 (US).

Published:

without international search report and to be republished upon receipt of that report

(72) Inventors; and

(75) Inventors/Applicants (for US only): SNITKIN, Eva, S. [US/US]; 219 Bank Street SE., Minneapolis, MN 55414

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COATED SLING MATERIAL

(57) Abstract: The present invention relates to a sling, methods of making and using a sling, and kits comprising a sling for treating urinary incontinence. The sling has multiple elongation properties that serve to improve the support of the urethra. The sling may comprise a coated material adapted for urethral suspension. The coated sling has properties that appear to enhance the sling elongation characteristics. The coated sling further includes properties that reduce its susceptibility to bacterial infections. The sling further includes properties to enhance the proper tensioning of the sling.

COATED SLING MATERIAL

FIELD OF THE INVENTION

The present invention generally relates to the repair of tissue defects in a patient, including such defects as hemia. The present invention specifically relates to devices and methods in the long-term cure of recurrent female urinary incontinence. More particularly, the present invention relates to slings for use in treating female urinary incontinence and methods of making and using the slings.

5

10

15

20

25

30

BACKGROUND OF THE INVENTION

Normal urination and continence is dependent upon normal function of the urinary tract, kidneys and nervous system. In addition, in women, continence requires correct coaptation and urethral support. Specifically, in order for continence to be maintained, the urethra must be supported and stabilized in its normal anatomic position behind the pubic bone, adjacent to the vaginal wall. The natural support system for the female urethra is a layer of support composed of pelvic and vaginal wall tissue and ligaments, which attach to the pubic bone. Relaxation, weakening or loss of this support system results in hypermobility of the urethra and bladder to an unnaturally low position within the pelvis. This defect contributes to about 30% of incontinence in women.

One form of incontinence, referred to as stress incontinence, is an involuntary loss of urine that occurs with increased abdominal pressure such as with coughing, sneezing, laughing, or lifting. Urethral hypermobility may be a result of pregnancy (one reason why stress incontinence is common in women who have had multiple pregnancies), or may be due to pelvic prolapse. In pelvic prolapse, there is a protrusion or falling of the bladder, urethra, or rectal wall into the woman's vaginal space. Additionally, in women with low estrogen levels such as in post-menopausal females, stress incontinence is more likely to occur due to decreased vaginal muscle tone resulting from the loss of estrogen.

Approaches for treating female urinary incontinence vary and include methods directed at elevating the urethra or the bladder neck (upper region of the urethra) to return it to its normal anatomical position behind the pubic bone. These methods include needle suspension procedures and sling procedures. The needle suspension procedure is a commonly used procedure which involves placement of sutures in the support tissue (fascia) on either side of the displaced urethra and attaching these

sutures to fixed sites such as bone and soft tissue. Therefore, a variety of devices have been developed to aid in the fixed attachment of the sutures to the support structures. A disadvantage with this approach, however, is that the tissue support structures being used for the urethra are themselves stretched or otherwise deficient, thereby, making them inefficient as support structures and a less effective solution.

5

10

15

20

25

30

Another approach for treating female incontinence is the sling procedure. In this procedure a sling is formed by taking a piece of human abdominal tissue (fascia) or a piece of synthetic material and using this as a platform to provide support and/or restore the urethra to its normal retropubic position. Slings made of biological tissue require either growing or harvesting autologous tissue or using processed cadaveric tissue. Therefore, these types of sling materials are sometimes undesirable in that they increase the expense, surgeon's time required and complexity of the procedure.

As an alternative to human tissue, prefabricated or synthetic slings have been developed for use in treating incontinence and are described, for example, in U.S. Patent No. 6,042,534. These slings are said to offer improvements to the sling procedure for treating incontinence in that the synthetic slings are supplied to the physician in shapes and dimensions adapted for urethral stabilization. This eliminates the need for sizing of the sling material by the surgeon during surgery, which greatly reduces the time required for the surgical procedure.

Another example of a synthetic sling and system for use in treating incontinence is described in U.S. Patent No. 6,039,686 issued March 21, 2000 to Kovac. The sling system of Kovac involves stabilizing the urethra using a mesh sling having an innovative mesh suturing pattern that is secured *in vivo* by short sutures attached to the posterior/inferior (lower, back) portion of the pubic bone instead of the superior (upper) portion of the pubic bone as with other methods.

The tissue and mesh used in prior slings can be fabricated or obtained from a variety of materials and sources. There does not appear to be any attention given to configuring, creating or modifying these slings in a manner to provide optimal elongation characteristics to the support tissue. Particular elongation properties are desirable in some circumstances, such as when the amount of tension or support at the region immediately surrounding the bladder neck of the urethra is important.

Tissue ingrowth, infection resistance and capacity to erode surrounding tissue are also factors in sling designs. The specific effect of the elasticity of the sling on these factors is not known in great detail.

In view of the above, although improvements in surgical treatment of urinary incontinence have been made, there is a need to provide even more improved sling systems so as to further enhance reliability and to better respond to patient kinetics.

SUMMARY OF THE INVENTION

5

10

15

20

25

30

In view of the foregoing, it is an object of the present invention to provide a surgical sling that addresses the limitations and disadvantages associated with prior devices and systems, yet meets the needs of the user.

A further object of the invention is to provide a sling apparatus having distinct elongation properties along its length and its width and that minimizes the complexities of the placement procedure for the surgeon.

A further object of the invention is to provide a surgical sling fabricated such that it has one elongation property in one direction and a second elongation property in a second direction.

An additional object of the invention is to provide a coating to a sling material that contributes to appropriate elongation property, improves biocompatibility and inhibits or resists infection.

An additional object of the invention is to provide a method of making and using a multiple elongation sling system for treatment of urinary incontinence. The system can include a surgical sling having several distinct elongation properties and adapted to be passed under the urethra for supporting the urethra in its normal anatomic position. When inserted into a patient, the sling can also prevent abnormal urethral descent in a patient.

An additional object of the invention is to provide a sling material made from a mesh wherein the mesh is coated but contains open holes or pores to promote tissue in-growth.

An additional object of the invention is to provide a sling material that provides visual indicia to the user that is indicative of a particular tensioned state of the sling material.

The present invention includes coated slings and slings having certain physical and biologic characteristics that increase the overall effectiveness and comfort of the sling once implanted in vivo. Such systems also include slings that provide visual indicia to the user indicating when the sling has been manipulated into a desired state, e.g., into a desired tension.

BRIEF DESCRIPTION OF THE DRAWINGS

- FIG. 1 is a view of an uncoated base material for use as a sling in accordance with one embodiment of the invention;
- FIGS. 2A 2B are views of a first embodiment of a sling in accordance with the present invention;
 - FIGS. 3A 3B are views of a second embodiment of a sling in accordance with the present invention;
 - FIG. 4 is a flow chart for fabricating a sling in accordance with one embodiment of the invention;
- 10 FIG. 5 is a schematic view of another preferred embodiment in accordance with the present invention;
 - FIGS. 6A and 6B are views of a sling material in accordance with one embodiment of the present invention and a method of determining tension in accordance with the present invention;
- 15 FIGS 7A and 7B are views of a sling material in accordance with another embodiment of the present invention and a method of determining tension in accordance with the present invention; and,
 - FIGS. 8A and 8B are views of a sling material in accordance with another embodiment of the present invention and a method of determining tension in accorance with the present invention.

20

25

30

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides efficient and reliable slings for use in treating males and females. The sling is particularly suitable for pelvic floor reconstruction surgery and for treating urinary incontinence. The features of the invention as described herein provide a surgical sling having at least two different elongation characteristics along its surface area. In addition, the slings may be coated with, for example, a silicone coating. Such coating is believed to contribute to the desired elongation properties of the mesh, assist with ensuring biocompatibility, and provide a carrier for anti-microbial agents.

Referring to Figure 1, an enlarged plan view of a material 10 according to one aspect of the invention includes a material that is a surgical mesh 12. Individual strands or filaments 14 collectively form a multifilament yarn 16 that can be woven or braided 18 to form the desired weave. The weave leads to a pattern of holes or pores 24.

Materials suitable for use in fabricating the coated slings of the present invention include man-made materials such as filamentous mesh materials. Filamentous mesh materials include synthetic fibers such as polyester, polyurethane, nylon, or polypropylene which can be woven or braided to form a mesh 12. The filaments in such materials may be oriented in a single direction or may be multidirectional.

5

10

15

20

25

30

35

As will be further described below, the pattern formed by the weave can be designed so as to provide a mesh material having directionally oriented elongation properties. In a preferred embodiment of the present invention, the mesh material comprises a weave pattern where the holes 24 have a diamond shape. As would be apparent to one skilled in the art, the degree of "stretch" or elongation properties in either direction of the mesh pattern can be adjusted as preferred by a user by altering the weave of the mesh material.

In a preferred embodiment, a synthetic filamentous material suitable for fabricating a mesh for use as a sling include a commercially available material comprised of a Rashel knit mesh made from 150 denier polyester yarn. Such a mesh has a hole size of approximately 1/32" (0.784 mm) and a weight of approximately 4.7 oz/yd. (133.25 gr/.914 m). The yarn is a multi-filament yarn. In another embodiment a mesh know as Mersilene™ may be used.

The weave of the mesh according to one aspect of the invention is such that it has greater elongation properties in one direction 20 than it does in a second direction 22 transverse (or perpendicular) to the first direction 20.

In a preferred embodiment wherein the mesh is cut in a rectangular, sling-like configuration, the elongation properties of the mesh in the longitudinal direction are such that the mesh will elongate in the range of about 24% – 28% beyond its normal state when placed in tension by a 20 lb. (9.072 kg) load. The elongation properties in a direction transverse (i.e., perpendicular) to the longitudinal direction, that is, in the latitudinal direction, are such that the mesh will elongate in the range of about 65% - 75% beyond its normal state when placed in tension by a 20 lb. (9.072 kg) load.

By virtue of the longitudinal direction having lesser elongation properties than the latitudinal direction, there is less tendency for the longitudinal edges of the sling to curl in on themselves when the sling is in tension along the longitudinal direction. This is a desired property along the longitudinal direction of the mesh insofar as an implanted sling that becomes curled in this manner can be more prone to cause tissue irritation and ultimately tissue erosion in the patient.

Conversely, by virtue of the latitudinal direction of the mesh sling having greater elongation properties, the sling provides greater flexibility and "give" in a direction parallel to the urethra. As a result, the sling can still serve its function of treating incontinence but it does so with less trauma and greater comfort since the sling is now more responsive to patient movements and activities.

5

10

15

20

25

30

These desirable properties of the mesh are particularly acute in sling operations where the sling is attached to the pubic bone at the sling's opposite longitudinal ends. That is, the properties of the invention are best utilized when the sling is attached to opposite sides of the pubic bone and placed in tension along its longitudinal axis. In this manner, elongation is allowed in the longitudinal direction with minimal edge curling while at the same time the elongation is enhanced in the latitudinal direction to promote responsiveness to patient movement. This result is believed to make the sling procedure a more clinically stable procedure that improves patient comfort.

Alternatively, in some surgical procedures, the sling may be placed in the body in a tension free rest position. Even in this tension free rest position, the sling according to the present invention is believed to resist edge curling when anatomical movement (e.g. a stress event such as a cough) places tension on the sling.

As depicted in Figures 2A-3B, the present invention further contemplates a sling wherein the above-described mesh material is coated with a substance to enhance its properties and, in some cases, provide a platform for the impregnation of therapeutic substances (drugs, antibiotics, etc.). One such coating may be silicone. In particular, when the material of the sling is constructed of individual filaments that have the potential for tissue ingrowth, the silicone 30 substantially coats the exposed surfaces of the filaments and fills in irregular surfaces of the filaments of the mesh material, thereby substantially preventing in-growth of tissue into the fibers of the yarn of the sling material. Minimizing the exposed surface area also reduces the ability of bacteria or microbes to reside within the mesh material if the sling is exposed to bacteria during the implantation procedure. This is particularly advantageous as it decreases the risk of infection to the patient following implantation of the sling. This also restricts tissue ingrowth into and between any fibers of the yarn, thereby further resisting infections.

As is evident from the figures, the coating is applied in a manner such that the holes or pores 24 of the mesh remain open and clear of silicone. That is, the exposed surfaces within the holes or pores 24 themselves remain open and free of silicone. As

a result, a sling is obtained that resists infection (due to the coating) but also promotes tissue in-growth (due to the holes or pores 24).

A synthetic sling fabric material that is coated with a substance such as silicone is also advantageous in that the coating can provide lubricating characteristics to the mesh that enables easier adjustment of the sling during the implantation procedure. Further, the silicone coating creates in the sling a composite structure of the fabric and the silicone that better interacts with the patient's tissue. The silicone also coats the yarn material to the degree that the yarn functions much like a monofilament. Such a monofilament is believed to be less prone to infection. It is also believed to lead to less erosion of the tissue.

5

10

15

20

25

30

35

A coating such as silicone provides a platform from which therapeutic substances like antibiotics or antimicrobial agents can be introduced to the patient. Such agents can be impregnated into the silicone coating or, alternatively, may be formulated with the composition comprising the silicone coating and applied during the coating procedure. In some embodiments, a silicone coating containing or impregnated with antibiotic agents may contain a drug that is formulated to be time-released. Examples of agents suitable for use include antibiotics and antimycotics such as, gentamicin, fungizone, rifampin or minocycline HCL. Other agents may also be incorporated in the silicone, such as, but not limited to antiseptic agents, radioopaque agents and other antimicrobial agents.

In a preferred embodiment of the invention, the coating of the sling will also impact the dual elongation properties of the sling. For example, the fabric mesh discussed previously, which is later coated with silicone, will result in a mesh that elongates in its longitudinal direction about 19.5% - 21.5% beyond its normal state when placed in tension at about 20 lbs. (9.072 kg) of force. Conversely, the mesh elongates in its latitudinal direction about 120%-130% beyond its normal state when placed in tension at about 20 lbs. (9.072 kg) of force. This is a desired result insofar as elongation properties are tending to be enhanced in the latitudinal direction (to provide patient comfort) but are tending to be minimized in the longitudinal direction (to reduce any curling propensities).

In this preferred embodiment, the reduced elongation properties in the longitudinal direction are believed to have been achieved as a result of holding the mesh in tension in the longitudinal direction at the time the mesh was coated. In other words, it appears that pre-stretching, or at least pre-tensioning the mesh in the longitudinal direction during the coating process, led to the reduction in elongation

properties in the longitudinal direction as compared to the elongation properties in the longitudinal direction in the uncoated mesh sling. As a result, it is contemplated as part of the invention, that, should it be desired to avoid reduction of the elongation properties in the longitudinal direction, the mesh should not be held in tension along the longitudinal direction and perhaps should be held free of tension altogether, or in uniform tension, or in tension along the latitudinal direction prior to silicone coating.

5

10

15

20

25

30

In this regard, a number of tests have been performed to more fully expand the explanation and implementation of the present invention. These tests involve the acquisition of data on the elongation properties of the sling according to how the sling has been processed with a silicone coating. The result of the tests are set forth in the following table.

Table A

5 Lb test load	Uncoated	Si Coated w/o Pre-Tension	Si Coated w/ Longitudinal Pre- Tension	Si Coated w <i>l</i> Latitudinal Pre- Tension
Longitudinal Elongation	8%	5%	2.5%	10.5%
Latitudinal Elongation	36%	N/A	65%	25%

As is evident from the table, there were four types of slings that were tested, namely: (1) an uncoated sling; (2) a sling that was not held in tension while being coated with silicone; (3) a sling that was held in longitudinal tension while being coated with silicone; and, (4) a sling that was held in latitudinal tension while being coated with silicone. As is also evident from the table, each of the four slings were tested for respective elongation properties both in the longitudinal direction and the latitudinal direction. These tests were conducted using a 5 lb tension-loading device.

The resulting data is consistent with the elongation figures discussed previously. For example, when the sling is coated with silicone while under longitudinal tension, there is a dramatic decrease in longitudinal elongation properties in the resulting sling accompanied with a dramatic increase in latitudinal elongation properties in the sling as compared to the corresponding elongation properties of an uncoated sling. In addition, a sling coated with silicone under latitudinal tension leads to a sling having increased longitudinal elongation properties accompanied with reduced latitudinal elongation properties. As a result, it can be seen that desirable elongation properties that would otherwise not be available under normal conditions can be "locked" into the sling during the coating process.

One embodiment of the invention that is particularly exemplary of a manner in which to exploit the invention is set forth in Figure 5. In this embodiment, a sling 500 is provided that has different elongation properties at different regions or zones on the sling. These regions are a result of molding separately manufactured strips or portions of coated fabric into a single sling 500.

5

10

15

20

25

30

35

For example, in one embodiment, the central region 502 of the sling 500 has been coated with silicone while in latitudinal tension thus giving this central region 502 a somewhat increased longitudinal elongation property and a somewhat decreased latitudinal elongation property over a non-pretensioned coated sling (see Table A).

The intermediate regions 504 of the sling 500 have been coated with silicone while in longitudinal pre-tension, thus giving the intermediate region 504 a dramatically decreased longitudinal elongation property and a dramatically increased latitudinal elongation property over a non-tensioned, coated sling. Moreover, the intermediate regions 504 may molded into place to form the sling in a transverse direction (i.e., rotated 90°) as compared to the configuration of the fabric in the central region 502. As a result the longitudinal and latitudinal elongation properties exhibited by these intermediate regions 504 of the sling 500 actually correspond to the latitudinal and longitudinal properties, respectively, set forth in Table A for the sling that was silicone coated while in longitudinal tension.

The end regions 506 of the sling 500 have been coated with silicone while in longitudinal tension thus giving the end regions 506 a decreased longitudinal elongation property and an increased latitudinal elongation property (see Table A). The end result is a sling 500 that provides varying elongation properties along the length of the sling 500 that can be best suited to mitigate undesirable curling tendencies of the sling while enhancing the desirable flexibility characteristics of the sling.

Although the aforesaid embodiment is disclosed as comprising discrete portions of coated fabric that are molded into a complete sling, this aspect of the invention is not so limited. For example, it is within the scope of the invention to create a similar "multi-zone" sling merely by coating various regions or zones of a unitary sling under differing tension parameters at these various regions or zones.

In view of the above disclosure, it will be seen that the dual elongation properties of the invention as well as the coating by a substance such as silicone, enhances and improves the efficiency of the sling when placed in the patient. Furthermore, the coating and method of coating improves the lubricity between the

mesh and the tissue and also appears to enhance the elongation properties of the sling. In other words, a sling in accordance with the present invention provides the needed long term support for effectively stabilizing the urethra to its normal anatomical position while also permitting temporary movement of the urethra (due to the dynamic nature of the patient's anatomy and movements) with the pelvis.

Depending upon the parameters of the coating process used, varying degrees of silicone thickness surrounding the mesh yarns can be obtained. However, in all circumstances, the holes or pores 24 remain open after coating. Referring to Figures 2A, 2B, 3A and 3B, depending upon the desire or need of the user, a sling can be coated so as to comprise a coated mesh material having a thickness ranging from about .024 inches (0.61 mm) to about .036 inches (0.914 mm) (Figures 3A, 3B) or from about .020 inches (0.508 mm) to about .025 inches (0.635 mm) (Figures 2A and 2B). In one embodiment, the thickness of the sling material in the uncoated state is about .020 inches (0.508 mm) plus or minus about 0.002 inches. In a preferred embodiment, the size of the holes or pores 24 after coating is preferably in the range of about .040 inches (1.016 mm) to about .055 inches (1.397 mm).

In a preferred embodiment, a silicone-coated sling will have a generally rectangular shape that is approximately 2-12 cm wide (more preferably 10 cm) and 5-20 cm long. In particular, a silicone-coated sling of the present invention will be of sufficient size and dimension so as to pass behind the urethra and support the urethra in its normal anatomic position when implanted in vivo. In addition, the silicone-coated sling should be adapted so as to be capable of preventing abnormal urethral descent under increased intra-abdominal pressure.

It is contemplated that the present invention can be used with a variety of sling systems and methods for treating urinary incontinence. For example, a coated sling in accordance with the present invention, can be used with the system for the long term cure of recurrent urinary female incontinence as described in co-pending U.S. Patent application Serial No. 09/236,212 filed January 1, 1999 (Kovac), entitled "System and Method for Treating Female Urinary Incontinence," the entire disclosure of which is hereby incorporated by reference. When used in such a system, a silicone-coated sling can be installed in vivo using the vaginal installation procedure as described in the application. Alternatively, a coated sling in accordance with the present invention can be prefabricated according to the dimensions and shapes as described, for example, in U.S. Patent No. 6,042,534 issued March 28, 2000 entitled "Stabilization sling for use in minimally invasive pelvic surgery" and installed as described in U.S.

Patent No. 6,042,534. A coated sling of the present invention can also be installed abdominally or laparoscopically using procedures well known in the art.

In addition, sheets of silicone coated fabric may be prepared in a similar manner for general pelvic floor reconstruction.

Method for Silicone Coating a Sling

5

10

15

20

25

30

Figure 4 illustrates one preferred embodiment of a process of applying a silicone coat to a mesh material for use as a sling. The method includes step 40 of providing a mesh material which can be manipulated for use as a sling. In a preferred method, a silicone dispersion is selected for use as the coating material. In step 40, a preferred mesh material is as previously described. The silicone dispersion is preferably a medical grade silicone dispersion. The silicone dispersion is a result of mixing equal parts (100 g each) of a silicone such as Medium 6820 with 5 parts (500 g) solvent such as Xylene. The dispersion can be mixed by stirring on a stir plate in a fume hood. Mixing should be performed for a minimum of 20 minutes with the container covered so as to minimize evaporation.

Next, in step 50, a container such as an aluminum pan is filled with the silicone dispersion for immersion of the mesh material. The pan should be kept covered (with foil, for example) when not in use, so as to prevent evaporation.

In step 60, the mesh material is placed into the dispersion mix and is held flat by use of, for example, 6" (15.24 cm) embroidery hoops. When using embroidery hoops, the mesh material should be pulled through the edges of the hoop until the mesh material is taut, flat, and constrained along most if not all of the peripheral edges of the mesh material. Care should be taken not to inordinately stretch the material as this could result in distortion of the holes of the mesh material or in uneven coating of the mesh material, which can affect the dual elongation aspect of the sling. The mesh material should be trimmed to be sized closely to the dimensions of the hoop so as to minimize material overlap. The hoop containing the mesh material is placed into the pan containing the silicone dispersion for about 15 seconds, or more, and then removed.

In other embodiments, the sling material can be held in tension at opposite ends of the sheet prior to applying the coating. As discussed previously, depending on which direction of the mesh is in tension during coating, differing elongation properties in the sling may be obtained.

In step 70, excess silicone dispersion 42 is removed by allowing the silicone to drip off of the mesh material as the hoop is placed flat over the pan for about 1-5 minutes.

In step 80, the coating within the holes of the mesh material are cleared. This can be performed by using a foot-controlled air nozzle having an air setting of approximately 55-psi and 600 pulses per minute. Using the air nozzle, the coated mesh material can be continuously sprayed to clear the openings until there are minimal or no holes filled with silicone dispersion mix. In one embodiment, the spraying is performed intermittently. For example, pulsed air may be used.

5

10

15

20

25

30

In step 90, the coated mesh material is rested, air-sprayed side up, for approximately 5 to 15 minutes.

In step 100, the entire procedure outlined above in steps 50 - 90 is then repeated with the exception that the second side of the mesh material is now air-sprayed so as to ensure a uniform distribution of the silicone coating over all surfaces of the mesh material.

The spraying steps are performed also to ensure that the holes or pores of the mesh are not filled or closed with silicone. As stated previously in one embodiment of the invention, the sling has been coated with silicone but still contains open holes or pores to promote tissue growth.

In a preferred embodiment, the entire procedure outlined in steps 50 - 100 is repeated until both sides of the mesh material have 2 coats or more of dispersion 120. During the repeating process, alternate sides of the mesh material may be airsprayed.

In step 140, the silicone coating is heated to set the silicone dispersion. This can be performed, for example, by hanging the hoops holding the mesh in an oven that is set at 160°C (+/- 10°) for about 20 minutes.

It is noted that the sling according to the present invention may be constructed using a batch process or a continuous process. For example, in a continuous process, the silicone dispersion may be placed in a large reservoir, and the strip material may be provided in an elongate, substantially continuous strip that is substantially continuously fed into the reservoir using, for example, rollers and/or mechanical clamping structures.

In step 160, the silicone coated mesh material is removed from the oven and allowed to cool. Following cooling, the material is then cut from the hoop. If desired,

an anti-microbial substance or medicament can be impregnated into the silicone elastomer in a subsequent process.

After removing the material from the hoops, the silicone coated mesh material can then be fabricated as desired into a sling for use in treating urinary incontinence. As described previously, a silicone coated mesh material of the present invention, can be used to fabricate a sling such as described in co-pending U.S. Application Serial No. 09/236,212, filed January 1, 1999 and then surgically implanted into a patient suffering from urinary incontinence.

5

10

15

20

25

30

35

In another embodiment, the sling material is configured in a long narrow elongated piece of mesh. The width is approximately the same width as a sling used in a patient. When coated, the edges of the material along the length of the material are coated with the silicone. When an elongated material is used in this manner, all that is required to obtain a sling suitable for use in a patient is to cut the elongated material through its width at the desired length of the sling. This will yield a sling that has the edges along the longitudinal side of the sling completely coated with silicone. In other words, since there is no necessary cutting in the longitudinal direction (because the material is already formulated to have the desired sling width) to obtain a desired size of sling, the integrity of the coating along the uncut edges remains intact, thus better ensuring the advantageous properties introduced in the sling as a result of coating.

A silicone coated sling as described herein can be fabricated into a variety of dimensions or can be manipulated to conform to a variety of sling specifications, depending upon user or manufacturer's preference. In addition, the coated sling can also be adapted so as to include structures to aid in the attachment or connection of the sling to the patient *in vivo*. It is also to be emphasized that silicone is only one coating that may be used, and, as such, is only exemplary, not limiting, in the context of the invention.

In still further embodiments in accordance with the present invention, it is desired to enable the user to more easily determine the presence and magnitude of tension in the sling material during placement of the sling. The ability to accurately make this determination will allow the user to adapt the fixation of the sling in the patient in a manner to maximize the potential of successfully treating the incontinence problem.

Referring to Figures 6A and 6B, a sling material 600 is shown in both the unstretched, condition (Figure 6A) and in the tensioned condition (Figure 6B). This

sling material 600 can be comprised of any of the types and variations of mesh material previously discussed in this specification or any other type of mesh material that allows an elongation of the sling when placed under tension.

5

10

15

20

25

30

35

When in the unstretched condition (Figure 6A) the sling 600 has a normal width 602 (e.g., approximately 5 cm) in the central region of the sling 600. When the sling 600 is placed into tension (Figure 6B), however, the sling 600 takes on a reduced width 604 (e.g., approximately 1 cm) in the central region of the sling. By virtue of this phenomenon, a mesh material having certain known elongation (discussed above) properties can be used so that when the sling 600 achieves the reduced width 604, a known tension thus exists in the sling. Moreover, this known tension can be selected to exist in the range that is most optimum for treating the incontinence. Furthermore, by using a mesh material in accordance with previously discussed embodiments, the optimum tension can be achieved without the undesirable curling in the mesh that can cause tissue erosion. In the end, a mesh material is provided that potentially minimizes many of the undesirable aspects of placing a sling into a patient while at the same time optimizing the placement so as to enhance the prospect of successfully treating the incontinence condition.

Referring to Figures 7A and 7B, another embodiment of a sling 700 that provides a visual tension indicia is disclosed. In this embodiment, the sling material is fabricated so that there is a geometrical pattern in the form of a square 702 visibly evident on the surface of the untensioned sling 700 (Figure 7A). However, as the sling is placed in tension, the geometrical pattern 702 becomes distorted. Moreover, using the known elongation properties of the sling, the sling can be fabricated such that when the geometrical pattern achieves a different known shape due to tensioning, say, for example, a circle, ellipse or polygonal structure with one or more arcuate portions (e.g. 702A), the sling will have achieved the desired tension for proper placement in the patient.

The invention as disclosed in the embodiment of Figures 7A and 7B is not limited to visual indicia in the form of geometrical patterns. For example, the visual indicia could be a series of seemingly random lines that, under the target tension, become alligned into a straight line or into a geometrical pattern such as a triangle. As another example, the visual indicia could be a collection of marks or characters that, under the target tension, become alligned to spell a word such as "OK," or "STOP," or "LIMIT." In one embodiment the word could even spell the manufacturer of the sling, such as "AMS."

The visual indicia described above could be integrated into the mesh material a variety of ways. For example, the mesh could actually be integrated into the fibers that are woven into the mesh so that the indicia is present upon weaving the material. In another example, the visual indicia could be added to the mesh as a component of a coating (e.g., silicone) applied to the mesh material.

5

10

15

20

25

30

35

Referring next to Figures 8A and 8B, an embodiment of the invention is disclosed wherein the visual tension indicia is in the form of changes in the weave of the mesh. For example, a mesh 800 could be used such that it takes on a substantially square hole pattern (Figure 8A) in the untensioned condition. Then, when the mesh 800 is stretched the hole pattern becomes distorted. Based on the known elongation properties of the mesh, the mesh can be manufactured such that a particular desired tension is present in the mesh when the hole material has changed into a different, recognizable pattern. In one embodiment, that new hole pattern could be a parallelogram structure as shown in Figure 8B.

It will be evident to the reader that the visual tension indicia component of the present invention is not limited to the isolated embodiments disclosed in the figures and that various combinations of visual tension indicia is also contemplated. For example, a mesh using a varying hole pattern indicia as in Figures 8A and 8B could be combined with either of the visual indicia ideas contemplated in the embodiments of Figures 6A, 6B, 7A and 7B. In the end, the principle to guide the use of indicia is that the user be better enabled to know when a desired tension has been achieved in the sling by simple visual observation.

The present invention provides a simple, safe and stable system for treating urinary incontinence. The invention, as described herein, with reference to preferred embodiments, provides a coated sling that supports an abnormally distended urethra to effectively remedy urinary incontinence.

Although the invention has been described in terms of particular embodiments and applications, one of ordinary skill in the art, in light of this teaching, can generate additional embodiments and modifications without departing from the spirit of or exceeding the scope of the claimed invention. Accordingly, it is to be understood that the drawings and descriptions herein are proffered by way of example to facilitate comprehension of the invention and should not be construed to limit the scope thereof.

All publications and patent applications in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated by reference.

What is claimed is:

1. A sling for insertion into a patient comprising:

a surgical sling adapted to support the urethra in its normal anatomic position and to prevent abnormal urethral descent under intraabdominal pressure;

said surgical sling comprising a length of material having a longitudinal axis, and a latitudinal axis;

wherein said material has a first elongation property along said longitudinal axis, and a second elongation property along said latitudinal axis.

said first and second elongation property being different from each other.

- 2. The sling as set forth in claim 1, wherein said second elongation property is greater than said first elongation property.
- 3. The sling as set forth in claim 1, wherein said first elongation property is approximately 8% elongation beyond a normal state of said sling material when said sling material is subjected to a tension of approximately 5 lbs.
- 4. The sling as set forth in claim 3, wherein said second elongation property is approximately 36% elongation beyond a normal state of said sling material when said sling material is subjected to a tension of approximately 5 lbs.
- 5. The sling as set forth in claim 1, wherein said first elongation property is in the range of approximately 24%-28% elongation beyond a normal state of said sling material when said sling is subjected to a tension of approximately 20 lbs.
- 6: The sling as set forth in claim 5 wherein said second elongation property is in the range of approximately 65%-75% elongation beyond a normal state of said sling material when said sling is subjected to a tension of approximately 20 lbs.
- 7. The sling as set forth in claim 1, wherein said sling is coated with a substance that enhances biocompatibility.
- 8. The sling as set forth in claim 7, wherein said material comprises a surgical mesh material.
- 9. The sling as set forth in claim 8, wherein said substance is silicone.

10. The sling as set forth in claim 9, wherein said coated mesh has a thickness within the range of approximately .024" (0.61 mm) to .036" (0.914 mm).

- 11. The sling as set forth in claim 7, wherein said material is impregnated with therapeutic agent.
- 12. The sling as set forth in claim 7, wherein said first elongation property is in the range of approximately 19.5-21.5% elongation beyond a normal state of said sling material when said sling material is subject to a tension of approximately 20 lbs.
- 13. The sling as set forth in claim 12 wherein said second elongation property is in the range of approximately 120-130% elongation beyond a normal state of said sling material when said sling material is subject to a tension of approximately 20 lbs.
- 14. The sling as set forth in claim 7, wherein said first elongation property is approximately 2.5% elongation beyond a normal state of said sling material when said sling material is subject to a tension of approximately 5 lbs.
- 15. The sling as set forth in claim 7, wherein said second elongation property is approximately 65% elongation beyond a normal state of said sling material when said sling material is subject to a tension of approximately 5 lbs.
- 16. The sling as set forth in claim 7, wherein said first elongation property is approximately 10.5% elongation beyond a normal state of said sling material when said sling material is subject to a tension of approximately 5 lbs.
- 17. The sling as set forth in claim 7, wherein said second elongation property is approximately 25% elongation beyond a normal state of said sling material when said sling material is subject to a tension of approximately 5 lbs.
- 18. A method of making a sling for treating urinary incontinence comprising:

 providing a mesh material suitable for constructing a sling for supporting a
 urethra, said mesh having a first elongation property in a longitudinal direction and a
 second, different, elongation property in a latitudinal direction;

providing a coating dispersion; coating said mesh material with said coating dispersion; and

manipulating said mesh material during said coating so as to create a predetermined value for said first and second elongation properties in said mesh material.

- 19. A method as set forth in claim 18, wherein said coating is performed using a silicone dispersion.
- 20. A method as set forth in claim 18, wherein said mesh material is held in pretension in a longitudinal direction during said coating.
- 21. A method as set forth in claim 18, wherein said mesh material is held in pretension in a latitudinal direction during said coating.
- 22. A method as set forth in claim 18, wherein said manipulating of said mesh includes holding said mesh in pre-tension.
- 23. A method according to claim 18, wherein the step of coating said mesh material includes the step of continuously coating an elongate strip of said material.
- 24. A method according to claim 18 further including the step of blowing fluid such as air on the coated mesh material.
- 25. A method according to claim 24 wherein the step of blowing air includes the step of using pulsed air.
- 26. A sling for insertion into a patient comprising:

a surgical sling adapted to support the urethra in its normal anatomic position and to prevent abnormal urethral descent under intraabdominal pressure;

said surgical sling comprising a length of material having a longitudinal axis, and a latitudinal axis;

wherein said sling comprises a plurality of regions along its longitudinal axis and wherein each region contains differing elongation properties from an immediately adjacent region.

27. A sling as set forth in claim 26, wherein said sling material has a coated central region having an increased longitudinal elongation property and a somewhat decreased latitudinal elongation property as compared to elongation properties of said central region in a normal state.

28. A sling as set forth in claim 27, wherein said sling material has a coated intermediate region on either side of said central region, each of said intermediate regions having a decreased longitudinal elongation property and an increased latitudinal elongation property as compared to elongation properties of each of said intermediate regions in a normal state.

- 29. A sling as set forth in claim 28, wherein said sling material has a coated end region adjacent each intermediate region, each of said end regions having a decreased longitudinal elongation property and an increased latitudinal elongation property as compared to elongation properties of each of said end regions in a normal state.
- 30. A method of restoring urethral anatomy in a patient suffering from urinary incontinence comprising the steps of:

providing a silicone coated sling,

inserting a silicone coated sling into the patient's pelvic cavity;

manipulating said sling so as to pass under a central region of the patient's urethra;

attaching each end portion of the sling to a posterior/inferior region of a right and a left pubic bone of the patient; and

positioning the sling so as to restore and stabilize the urethra to a position that maintains urinary continence by orienting said sling such that said sling has a first elasticity in a direction spanning across the urethra and a second, different elasticity in a direction along the axis of said urethra.

- 31. A method according to claim 30 wherein the step of providing the silicone coated sling includes the step of providing a sling wherein the first elasticity is more than the second elasticity.
- 32. A method according to claim 30 wherein the step of providing the silicone coated sling includes the step of providing a sling wherein the first elasticity is less than the second elasticity.
- 33. A method of placing a sling in a patient for the treatment of urinary incontinence comprising:

inserting a sling into the patient's pelvic cavity, the sling having indicia capable or indicating tension in the sling;

manipulating said sling such that it passes underneath a central region of the patient's urethra;

tensioning said sling until said sling achieves a predetermined tension as indicated by visual indicia present on said sling; and,

securing said sling within said patient.

- 34. A method according to claim 33, wherein tensioning said sling includes observing visual indicia in the form of a predetermined width reduction in said sling.
- 35. A method according to claim 33, wherein tensioning said sling includes observing visual indicia having the form of a geometric pattern.
- 36. A method according to claim 33, wherein tensioning the sling includes observing a geometric pattern having the form of a distortion in a hole pattern of the sling material.
- 37. A method according to claim 33, wherein tensioning the sling includes observing a geometric pattern in the form of a distorted shape integrated onto the sling.
- 38. A method according to claim 33, wherein tensioning said sling includes observing visual indicia in the form of words.
- 39. A sling suitable for use in a sling procedure to treat urinary incontinence comprising:

a mesh material having a predetermined length and a width;
said mesh material having predetermined elongation properties;
said mesh having a predetermined visual indicia present on said mesh
corresponding to the presence of a predetermined tension in said sling, said
predetermined visual indicia being absent from said mesh when said sling is free from tension.

- 40. A sling according to claim 39, wherein said visual indicia is a predetermined width of said sling.
- 41. A sling according to claim 39, wherein said visual indicia is a predetermined geometrical pattern of said sling.

42. A sling according to claim 41, wherein said predetermined geometrical pattern is a hole pattern in said mesh.

- 43. A sling according to claim 41, wherein said predetermined geometrical pattern is a geometrical shape integrated onto said mesh.
- 44. A sling according to claim 39, wherein said visual indicia is a word present on said sling.




FIG. 1

SUBSTITUTE SHEET (RULE 26)

BEST AVAILABLE COPY




FIG. 2A




FIG. 2B SUBSTITUTE SHEET (RULE 26)

REST AVAILABLE COPY






FIG. 3A




F.16.3B

SUBSTITUTE SHEET (RULE 26)


BEST AVAILABLE COPY



SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)




Fig. 8A




Fig. 8B

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 14 March 2002 (14.03.2002)

(10) International Publication Number WO 02/19945 A3

(51) International Patent Classification7: D04B 21/18

A61F 2/00,

(21) International Application Number: PCT/US01/27306

(22) International Filing Date:

4 September 2001 (04.09.2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/230,647

7 September 2000 (07.09.2000)

(71) Applicant (for all designated States except US): AMERI-CAN MEDICAL SYSTEMS, INC. [US/US]; 10700 Bren Road West, Minnetonka, MN 55343 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SNITKIN, Eva, S. [US/US]; 219 Bank Street SE., Minneapolis, MN 55414 (US). WESTRUM, John, W., Jr. [US/US]; 8690 Oak Hill Circle, Prior Lake, MN 55372 (US). CABAK, James, E. [US/US]; 3725 Ximines Lane North, Plymouth, MN 55441


- (74) Agents: INSKEEP, James, W. et al.; Oppenheimer Wolff & Donnelly LLP, Suite 700, 840 Newport Center Drive, Newport Beach, CA 92660-7007 (US).
- (81) Designated States (national): AU, CA, JP, US.
- (84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FJ, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 10 May 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COATED SLING MATERIAL



(57) Abstract: The present invention relates to a sling, methods of making and using a sling, and kits comprising a sling for treating urinary incontinence. The sling has multiple elongation properties that serve to improve the support of the urethra. The sling may comprise a coated material adapted for urethral suspension. The coated sling has properties that appear to enhance the sling elongation characteristics. The coated sling further includes properties that reduce its susceptibility to bacterial infections. The sling further includes properties to enhance the proper tensioning of the sling.

ational Application No PCT/US 01/27306

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61F2/00 D04B21/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61F D04B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
χ	DE 196 13 317 A (SGRO JEAN CLAUDE) 10 October 1996 (1996-10-10)	1
A	table	18
X	US 6 042 536 A (RYDELL MARK A ET AL) 28 March 2000 (2000-03-28)	1,7
Y A	column 3, line 4 - line 55; figure 3	8,9 39,41,42
Y	FR 2 737 106 A (COUSIN BIOTECH) 31 January 1997 (1997-01-31)	8,9
Α	claims 1,5,6	18,19
X	US 6 042 534 A (GELLMAN BARRY N ET AL) 28 March 2000 (2000-03-28) cited in the application	1
Y A	column 7, line 42 -column 8, line 50 column 9, line 58 - line 67	39,41,42 26

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.		
Special categories of cited documents: 'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the international filing date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed	 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone 'Y' document of particular relevance; the claimed invention cannot be considered to involve an invention step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. '8' document member of the same patent family 		
Date of the actual completion of the international search 28 February 2002	Date of mailing of the international search report $06/03/2002$		
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Authorized officer Wolf, C		

h iational Application No PCT/US 01/27306

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT				
ategory *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Y	US 5 290 217 A (CAMPOS LUIS I) 1 March 1994 (1994-03-01) abstract	39,41,42		
X	EP 0 159 502 A (AMERICAN CYANAMID CO) 30 October 1985 (1985-10-30)	1		
Α	page 5, line 13 - line 28	26		
Α .	WO 98 58598 A (HAINDL HANS) 30 December 1998 (1998-12-30) page 10, line 1 - line 12	1,18,26		
A	US 5 657 648 A (IVES ROBERT K ET AL) 19 August 1997 (1997-08-19) abstract	1		
A	US 5 360 628 A (BUTLAND CHARLES L) 1 November 1994 (1994-11-01) abstract	19		
A	EP 0 265 157 A (ETHICON INC) 27 April 1988 (1988-04-27) column 7, line 12 - line 25; figure 8	41		
·				

Information on patent family members

I. lational Application No
PCT/US 01/27306

			5.47			01/2/306
	atent document d in search report		Publication date		Patent family member(s)	Publication date
DE	19613317	Α	10-10-1996	FR	2732582 A1	11-10-1996
				DE	19613317 A1	10-10-1996
				ES	1033775 U1	16-10-1996
		+		IT	MI960253 U1	03-10-1997
US	6042536	Α	28-03-2000	EP	1065992 A1	10-01-2001
				WO	0009039 A1	24-02-2000
				US 	6110101 A	29-08-2000
FR	2737106	Α	31-01-1997	FR	2737106 A1	31 - 01-1997
US	6042534	Α	28-03-2000	AU	6329598 A	08-09-1998
				EP	0983033 A1	08-03-2000
				JP	2001511685 T	14-08-2001
				WO	9835632 A1	20 - 08-1998
US	5290217	Α	01-03-1994	NONE		
EP	0159502	Α	30-10-1985	US	4633873 A	06-01-1987
				AU	574457 B2	07-07-1988
				AU	4164185 A	31-10-1985
				CA	1322915 A1	12-10-1993
				DE	3587563 D1	14-10-1993
				DE	3587563 T2	14-04-1994
				DK	186385 A	27-10-1985
				EP	0159502 A2	30-10-1985
				ES	542568 DO	16-05-1986
				ES	8606919 A1	16-10-1986
				FI	851633 A ,B,	27-10-1985
				GR	850997 A1	25-11-1985
				HK	67895 A	12-05-1995
			•	IL	74752 A	16-08-1991
				JP	5054352 B	12-08-1993
				JP	60234667 A	21-11-1985
				JP	2000093496 A	04-04-2000
				KR	9300688 B1	29-01-1993
				NO	851663 A ,B,	28-10-1985
				PH	23747 A	03-11-1989
				PT SG	80340 A ,B	01-05-1985
				US US	9590511 A2 4838884 A	18-08-1995 13 - 06-1989
				ZA	4838884 A 8503112 A	24-12-1985
 ⊌∩	9858598	Α	30-12-1998	DE	19826675 A1	04-03-1999
пU	7030330	^	20 17-1330	DE	29824017 U1	25-05-2000
				WO	9858598 A1	30-12-1998
				EP	0991373 A1	12-04-2000
US	5657648	Α	19-08-1997	US	5765401 A	16-06-1998
us Us	5360628	A	01-11-1994	US	5194289 A	16-03-1993
-	-	• •		US	4882195 A	21-11-1989
				AU	6093894 A	15-08-1994
				EP	0632765 A1	11-01-1995
				WO	9416902 A1	04-08-1994
				US	5599578 A	04-02-1997
		Α	27-04-1988	FR	2605214 A1	22-04-1988

Information on patent family members

PCT/US 01/27306

Patent family member(s)		Publication date
DE 37 DE 37 EP 02 JP 25 JP 631	83317 D1 83317 T2 65157 A1 67419 B2 02754 A	24-03-1992 11-02-1993 13-05-1993 27-04-1988 25-12-1996 07-05-1988 07-11-1989
	DE 37 DE 37 EP 02 JP 25 JP 631	DE 3783317 D1 DE 3783317 T2 EP 0265157 A1 JP 2567419 B2 JP 63102754 A

Form PCT/ISA/210 (patent family annex) (July 1992)